http://www.news-medical.net/news/200...st-tumors.aspx
"Evaluation of HER-2 status should consider the costs of treatment as well as the potential benefits of therapy," Press said. "And the cost of the diagnostic test is minimal compared with the cost of the medications. More accurate assignment of patients to treatment more than offsets the costs of erroneously treating women whose breast cancers lack HER-2 amplification.
In addition, there is the human cost of failing to treat women whose breast cancers have HER-2 amplification."
"
An issue with FISH for HER-2 testing is that up to 2 percent of breast cancers have FISH ratios at or near the cutoff level. However, we are aware of no published data demonstrating that patients with borderline HER-2 amplification respond less favorably to trastuzumab and lapatinib," he said.
Any idea if he's saying borderline positive or borderline negative?
Threaded Mode